TABLE 6.
Efficacy
| Number of patients (%) | |||
|---|---|---|---|
| All | Schedule A | Schedule B | |
| Best response | |||
| CR | 3/38 (7.9) | 3/22 (13.6) | 0/16 (0) |
| PR | 12/38 (31.6) | 7/22 (31.8) | 5/16 (31.2) |
| SD | 17/38 (44.7) | 9/22 (40.9) | 8/16 (50) |
| PD | 6/38 (15.7) | 3/22 (13.6) | 3/16 (18.7) |
| Clinical benefit (CR, PR, or SD) | 32/38 (84.2) | 19/22 (86.3) | 13/16 (81.2) |
| Best response, prior PARPi | |||
| CR | 0/5 (0) | ||
| PR | 1/5 (20) | ||
| SD | 3/5 (60) | ||
| PD | 1/5 (20) | ||
| Clinical benefit (CR, PR, or SD) | 4/5 (80) | ||
| Patients receiving ≥6 cycles of maintenance therapy | |||
| Total | 12/38 (31.6) | 10/22 (45.4) | 2/16 (12.5) |
| Duration of maintenance (months) | |||
| Median | 12.86 | ||
| Range | 5.5–55.5+ | ||
| Tumor type | |||
| Breast | 5 | ||
| Ovarian | 2 | ||
| Cutaneous SCC | 2 | ||
| Adenoid cystic carcinoma | 1 | ||
| Uterine leiomyosarcoma | 1 | ||
| Urothelial | 1 | ||